Canaccord Genuity Maintains a 'Hold' on RPC (RES); Dividend Help
Get Alerts RES Hot Sheet
Price: $6.36 --0%
Rating Summary:
6 Buy, 18 Hold, 11 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 5 | New: 25
Rating Summary:
6 Buy, 18 Hold, 11 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 5 | New: 25
Join SI Premium – FREE
Canaccord Genuity maintains a 'Hold' on RPC Inc. (NYSE: RES) price target of $24.00.
Canaccord analyst, Scott Burk, said, "RES reported in-line results and boosted its dividend. The stock has outperformed peers (ex-CPX) by ~15% since August, but does have 36% upside potential to our target based on trough multiples."
"Dividends help. RPC increased its dividend 25% to $0.40/sh or 2.3% yield. While not high enough in our view to significantly improve stock valuation, we agree with management that dividends are an important part of shareholder returns over time."
For more ratings news on RPC Inc. click here and for the rating history of RPC Inc. click here.
Shares of RPC Inc. closed at $17.60 yesterday.
Canaccord analyst, Scott Burk, said, "RES reported in-line results and boosted its dividend. The stock has outperformed peers (ex-CPX) by ~15% since August, but does have 36% upside potential to our target based on trough multiples."
"Dividends help. RPC increased its dividend 25% to $0.40/sh or 2.3% yield. While not high enough in our view to significantly improve stock valuation, we agree with management that dividends are an important part of shareholder returns over time."
For more ratings news on RPC Inc. click here and for the rating history of RPC Inc. click here.
Shares of RPC Inc. closed at $17.60 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Lowe's (LOW) PT Lowered to $275 at Guggenheim
- HomeTrust Bancshares (HTB) PT Raised to $57 at Stephens
- Needham Starts Faeth Therapeutics (FTH) at Buy
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
DividendSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share